{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-047013","form_type":"8-K","ticker":"BTAI","cik":"0001720893","company_name":"BioXcel Therapeutics, Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.465133+00:00","generated_at":"2026-05-21T23:56:48.473419+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"BioXcel Q1 net loss $7.3M; SERENITY At-Home trial fully enrolled, data H2 2025","bullets":["Net revenue from IGALMI fell to $168K in Q1 2025 from $582K in Q1 2024.","Net loss of $7.3M improved from $26.8M YoY on lower R&D and SG&A costs.","Cash and equivalents $31M as of March 31, 2025.","SERENITY At-Home pivotal Phase 3 trial fully enrolled; topline data expected H2 2025.","TRANQUILITY In-Care Phase 3 trial for Alzheimer's agitation is advancing toward initiation."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-047013","json":"https://secwatch.observer/filing/0001104659-25-047013.json","markdown":"https://secwatch.observer/filing/0001104659-25-047013.md","text":"https://secwatch.observer/filing/0001104659-25-047013.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925047013/0001104659-25-047013-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1720893/000110465925047013/tm2514754d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:56:48.473419+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}